Maze Therapeutics, Inc.'s Lock-Up Period To Expire on July 30th (NASDAQ:MAZE)

Maze Therapeutics' (NASDAQ:MAZE - Get Free Report) lock-up period will end on Wednesday, July 30th. Maze Therapeutics had issued 8,750,000 shares in its IPO on January 31st. The total size of the offering was $140,000,000 based on an initial share price of $16.00. After the expiration of Maze Therapeutics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on MAZE. HC Wainwright started coverage on Maze Therapeutics in a research report on Wednesday. They set a "buy" rating and a $34.00 price target on the stock. Guggenheim reaffirmed a "buy" rating and set a $19.00 price objective on shares of Maze Therapeutics in a report on Wednesday, April 2nd. Finally, Wedbush started coverage on shares of Maze Therapeutics in a research note on Tuesday, July 8th. They set an "outperform" rating and a $17.00 target price for the company. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $25.60.

Maze Therapeutics Stock Up 2.2%

Shares of NASDAQ MAZE traded up $0.37 during mid-day trading on Friday, reaching $16.82. The company's stock had a trading volume of 51,167 shares, compared to its average volume of 141,521. The business has a 50-day simple moving average of $13.07. Maze Therapeutics has a 1-year low of $6.71 and a 1-year high of $19.19.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).

Institutional Investors Weigh In On Maze Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. TRV GP IV LLC acquired a new stake in Maze Therapeutics in the 1st quarter valued at approximately $66,874,000. Frazier Life Sciences Management L.P. purchased a new stake in shares of Maze Therapeutics in the 1st quarter valued at $45,460,000. ARCH Venture Management LLC acquired a new position in Maze Therapeutics during the 1st quarter worth about $45,362,000. Matrix Capital Management Company LP purchased a new stake in Maze Therapeutics during the first quarter worth about $27,373,000. Finally, Alphabet Inc. purchased a new position in shares of Maze Therapeutics in the first quarter valued at approximately $26,561,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.